MILAN, ITALY–(Marketwired – Sep 22, 2013) – Versartis, Inc. today released the latest positive results from the company’s ongoing VERTICAL clinical trial of VRS-317, its proprietary long-acting form of recombinant human growth hormone (rhGH), at the 9th Joint Meeting of Paediatric Endocrinology in Milan. The most recent data from this trial in pediatric patients were presented by George M. Bright, MD, Versartis Vice President of Medical Affairs, in an oral discussion titled “A Phase 1b/2a Study of a New Long-acting Growth Hormone (VRS-317) in Pre-pubertal Children with Growth Hormone Deficiency (GHD).” All currently approved growth hormone drugs require daily injections and consequently pose considerable challenges to patients with GHD. In contrast, VRS-317 is being developed to provide up to once-monthly dosing and promises to improve patients’ ability to adhere to their therapy regimen and to improve their overall treatment outcomes.

Source: http://www.marketwired.com/mw/release.do?id=1833284&sourceType=3

This entry was posted on Sunday, September 22nd, 2013 at 1:30 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.